Roche (RHHBY) announced that the FDA has approved the subcutaneous (SC) formulation of the blockbuster immunotherapy drug Tecentriq (atezolizumab).The SC formulation was approved under the brand name Tecentriq Hybreza (atezolizumab and hyaluronidase-tqjs).Per Roche, the approval makes Tecentriq Hybreza the first and only subcutaneous anti-PD-(L)1 cancer immunotherapy in the United States.Year to date, Roche’s shares have gained 8% compared with the industry’s 25.4% growth.Image Source: Zacks Investment Rese ...